Effects of Bedtime Dosing With Suvorexant and Zolpidem on Balance and Psychomotor Performance in Healthy Elderly Participants During the Night and in the Morning

PURPOSE/BACKGROUND

This study was designed as an early assessment of the safety of the orexin receptor antagonist suvorexant, but also included exploratory assessments of balance and psychomotor performance that are the focus of this report.

METHODS/PROCEDURES

This was a double-blind, randomized, 3-period, crossover, phase 1 study. Balance and psychomotor performance were evaluated during the night in 12 healthy elderly participants after bedtime administration of suvorexant 30 mg (a supratherapeutic dose), the GABAergic agonist zolpidem 5 mg (the recommended dose in the elderly), or placebo. Balance (body sway measured by platform stability) and psychomotor performance (measured by choice reaction time) were assessed predose and at 1.5, 4, and 8 hours postdose in each period. Memory (measured by word recall) was assessed predose and at 4 hours postdose.

FINDINGS/RESULTS

At 1.5 hours after nighttime administration of each drug (the approximate time of their anticipated maximal plasma concentrations), both zolpidem and suvorexant increased body sway versus placebo, with a greater increase for zolpidem than suvorexant. Suvorexant increased choice reaction time compared with placebo or zolpidem at 1.5 hours. There were no treatment differences on body sway or choice reaction time at 4 or 8 hours, or on word recall at 4 hours.

IMPLICATIONS/CONCLUSIONS

These exploratory data suggest that a 30-mg dose of suvorexant (supratherapeutic) and a 5-mg dose of zolpidem (recommended dose in the elderly) impaired balance at 1.5 hours in healthy elderly people, with potentially less impairment for suvorexant relative to zolpidem, but no treatment differences on body sway or psychomotor performance at 4 and 8 hours. Because of their exploratory nature, these findings and their clinical relevance, if any, require confirmation in a prospective study.

Effects of General Fatigue Induced by Exhaustive Exercise on Posture and Gait Stability of Healthy Young Men

Bipedal walking is a composite task requiring integration of many control circuitries in the brain and spinal cord. The present study was carried out to verify whether an increase in blood lactate, such as that associated with a high intensity exercise, is able to significantly modify the qualitative and/or quantitative aspects of human walking. Eighteen healthy physically male participants, aged between 20 and 24 years (M = 21.8, SD = 1.22), were recruited for the study. For this purpose, the experimental protocol included the measure of blood lactate levels with the aim of assessing possible relations between lactate blood values and different aspect of walking after an exhaustive exercise. An exhaustive exercise was associated with a strong increase of blood lactate levels and produced a significant worsening in the ability to maintain the bipodalic upright posture as well as the fluidity of walking. Our results suggest that exhausting bouts impose greater challenges on postural control.

Postural Control and Stress Exposure in Young Men: Changes in Cortisol Awakening Response and Blood Lactate

Background: It has recently been noticed that the quantity of stress affects postural stability in young women. The study was conducted with the goal of investigating whether increased stress may damagingly effect posture control in 90 young men (71 right-handed and 19 left-handed) while maintaining an upright bipedal posture, while keeping their eyes open or closed. Perceived Stress Scale (PSS) was administered and changes in free cortisol levels were monitored (Cortisol Awakening Response, CAR) in order to evaluate the amount of stress present during awakening, while the Profile of Mood States (POMS) was used to estimate distress on the whole. Posture control was evaluated with the use of a force platform, which, while computing a confidence ellipse area of 95%, was engaged by the Center of Pressure through five stability stations and was sustained for a minimum of 52 s, with and without visual input. Another goal of the experiment was to find out whether or not cortisol increases in CAR were linked with rises of blood lactate levels. Results: CAR, PSS and POMS were found to be extensively related. Furthermore, it has been observed that increases in salivary cortisol in CAR are associated with small but significant increases in blood lactate levels. As expected, stress levels did affect postural stability. Conclusions: The results of the present study confirm that the level of stress can influence postural stability, and that this influence is principally obvious when visual information is not used in postural control.

Postural Control and Stress Exposure in Young Men: Changes in Cortisol Awakening Response and Blood Lactate

BACKGROUND

It has recently been noticed that the quantity of stress affects postural stability in young women. The study was conducted with the goal of investigating whether increased stress may damagingly effect posture control in 90 young men (71 right-handed and 19 left-handed) while maintaining an upright bipedal posture, while keeping their eyes open or closed. Perceived Stress Scale (PSS) was administered and changes in free cortisol levels were monitored (Cortisol Awakening Response, CAR) in order to evaluate the amount of stress present during awakening, while the Profile of Mood States (POMS) was used to estimate distress on the whole. Posture control was evaluated with the use of a force platform, which, while computing a confidence ellipse area of 95%, was engaged by the Center of Pressure through five stability stations and was sustained for a minimum of 52 s, with and without visual input. Another goal of the experiment was to find out whether or not cortisol increases in CAR were linked with rises of blood lactate levels.

RESULTS

CAR, PSS and POMS were found to be extensively related. Furthermore, it has been observed that increases in salivary cortisol in CAR are associated with small but significant increases in blood lactate levels. As expected, stress levels did affect postural stability.

CONCLUSIONS

The results of the present study confirm that the level of stress can influence postural stability, and that this influence is principally obvious when visual information is not used in postural control.

Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects

A double-blind crossover study investigated psychomotor effects, pharmacokinetics, and safety of the orexin receptor antagonist suvorexant with and without alcohol. Healthy adults (n=31) were randomized to receive placebo or suvorexant (40 mg) plus placebo solution or alcohol (0.7 g/kg) in each of four treatments (single doses; morning administration). The US Food and Drug Administration approved suvorexant dose is 10 mg (up to 20 mg) daily. Pharmacodynamic effects were assessed using tests of digit vigilance (DVT; primary endpoint), choice reaction time, digit symbol substitution, numeric working memory, immediate/delayed word recall, body sway and subjective alertness. Suvorexant alone did not significantly affect DVT reaction time, but did impact some pharmacodynamic tests. Suvorexant with alcohol increased reaction time versus either alone (mean difference at 2 h: 44 ms versus suvorexant, p<0.001; 24 ms, versus alcohol, p<0.05) and had additive negative effects on tests of vigilance, working/episodic memory, postural stability and alertness. No effects of suvorexant alone or with alcohol were observed by 9 h. No important changes in pharmacokinetic parameters were observed upon co-administration. All treatments were generally well tolerated without serious adverse events. In conclusion, co-administration of 40 mg suvorexant and 0.7 g/kg alcohol had additive negative psychomotor effects. Patients are advised not to consume alcohol with suvorexant.

Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease

OBJECTIVES

There is a general concern that hypnotic medications in patients with respiratory disorders have the potential to decrease respiratory effort and blunt the arousal response to hypoxemia which may lead to sleep breathing disorders. We investigated whether suvorexant, an orexin receptor antagonist approved for treatment of insomnia at a maximum daily dose of 20 mg in the US, causes sleep breathing disorders in patients with chronic obstructive pulmonary disease (COPD).

DESIGN

This was a randomized, double-blind, placebo-controlled, 2-period, cross-over, study performed in 9 sleep laboratories/clinical research units in the United States. The participants were 25 COPD patients aged 39-72 y with mild-to-moderate airflow limitation based on GOLD spirometry criteria. In each period, patients received suvorexant (40 mg in <65 y-olds; 30 mg in ≥65 y-olds) or placebo for four consecutive nights. Respiratory function during sleep was measured by oxygen saturation using pulse oximetry (SpO2, primary endpoint) and Apnea Hypopnea Index (AHI, secondary endpoint). The study was powered to rule out a difference between treatments of -2 percentage points in SpO2 on Day 4.

RESULTS

There was no treatment effect following single and multiple doses of suvorexant on mean SpO2 during total sleep time (Day 1: suvorexant = 93.14%, placebo = 93.24%, difference = -0.10 [90% CI: -0.50, 0.31]; Day 4: suvorexant = 93.38%, placebo = 92.99%, difference = 0.39 [90% CI: -0.12, 0.91]). There was no clinically meaningful increase in mean AHI by suvorexant compared with placebo on Day 1 (difference = 0.72 [90% CI: -0.60, 2.04]) or Day 4 (difference = 2.05 [90% CI: 0.33, 3.77]).

CONCLUSIONS

These data do not suggest an overt respiratory depressant effect with 30-40 mg daily doses of suvorexant, up to twice the maximum recommended dose for treating insomnia in the US, in patients with mild-to-moderate COPD. Trial registration Clinicaltrials.gov identifier: NCT01293006.

Stress exposure and postural control in young females

The aim of this study was to determine if heightened stress had an adverse affect on the postural control of 14 young right‑handed females during quiet standing in either the presence or the absence of visual input. The level of stress was evaluated by measuring the free cortisol response to awakening (cortisol awakening response; CAR) and by employing the perceived stress scale (PSS). Overall mood disturbance was measured using the profile of mood states (POMS). Postural control was evaluated using a force platform by measuring the 95% confidence ellipse area described by the center of pressure during 5 balance positions maintained for at least 52 sec, each with open and closed eyes. The results of this study revealed a significant positive correlation between CAR, PSS and POMS for each of the studied subjects. Furthermore, it was observed that whilst the level of stress was capable of influencing postural stability, this influence was particularly evident when no visual information was available. Additionally, it was determined that maintenance of posture is easier when the dominant foot is ahead, regardless of visual input.

Transcranial direct current stimulation reduces the cost of performing a cognitive task on gait and postural control

This proof-of-concept, double-blind study was designed to determine the effects of transcranial direct current stimulation (tDCS) on the 'cost' of performing a secondary cognitive task on gait and postural control in healthy young adults. Twenty adults aged 22 ± 2 years completed two separate double-blind visits in which gait and postural control were assessed immediately before and after a 20 min session of either real or sham tDCS (1.5 mA) targeting the left dorsolateral prefrontal cortex. Gait speed and stride duration variability, along with standing postural sway speed and area, were recorded under normal conditions and while simultaneously performing a serial-subtraction cognitive task. The dual task cost was calculated as the percent change in each outcome from normal to dual task conditions. tDCS was well tolerated by all subjects. Stimulation did not alter gait or postural control under normal conditions. As compared with sham stimulation, real tDCS led to increased gait speed (P = 0.006), as well as decreased standing postural sway speed (P = 0.01) and area (P = 0.01), when performing the serial-subtraction task. Real tDCS also diminished (P < 0.01) the dual task cost on each of these outcomes. No effects of tDCS were observed for stride duration variability. A single session of tDCS targeting the left dorsolateral prefrontal cortex improved the ability to adapt gait and postural control to a concurrent cognitive task and reduced the cost normally associated with such dual tasking. These results highlight the involvement of cortical brain networks in gait and postural control, and implicate the modulation of prefrontal cortical excitability as a potential therapeutic intervention.

The complexity of standing postural control in older adults: a modified detrended fluctuation analysis based upon the empirical mode decomposition algorithm

Human aging into senescence diminishes the capacity of the postural control system to adapt to the stressors of everyday life. Diminished adaptive capacity may be reflected by a loss of the fractal-like, multiscale complexity within the dynamics of standing postural sway (i.e., center-of-pressure, COP). We therefore studied the relationship between COP complexity and adaptive capacity in 22 older and 22 younger healthy adults. COP magnitude dynamics were assessed from raw data during quiet standing with eyes open and closed, and complexity was quantified with a new technique termed empirical mode decomposition embedded detrended fluctuation analysis (EMD-DFA). Adaptive capacity of the postural control system was assessed with the sharpened Romberg test. As compared to traditional DFA, EMD-DFA more accurately identified trends in COP data with intrinsic scales and produced short and long-term scaling exponents (i.e., α(Short), α(Long)) with greater reliability. The fractal-like properties of COP fluctuations were time-scale dependent and highly complex (i.e., α(Short) values were close to one) over relatively short time scales. As compared to younger adults, older adults demonstrated lower short-term COP complexity (i.e., greater α(Short) values) in both visual conditions (p>0.001). Closing the eyes decreased short-term COP complexity, yet this decrease was greater in older compared to younger adults (p<0.001). In older adults, those with higher short-term COP complexity exhibited better adaptive capacity as quantified by Romberg test performance (r(2) = 0.38, p<0.001). These results indicate that an age-related loss of COP complexity of magnitude series may reflect a clinically important reduction in postural control system functionality as a new biomarker.

Effects of prolonged-release melatonin and zolpidem on postural stability in older adults

OBJECTIVES

A prolonged-release formulation of melatonin (PR-M) is indicated for insomnia in patients aged 55 years and older. Because hypnotics result in impairments of body sway, it was important to evaluate the effect of 2 mg PR-M on postural stability in older adults at night.

METHODS

Twenty-four healthy volunteers (12 women, 12 men, aged 55-64 years) completed a randomized, double-blind, single-dose, three-way crossover study of postural stability of PR-M 2 mg, zolpidem 10 mg (active control) or placebo. Subjects were tested for body sway 30 min before, 1.5 and 4 h after dosing. Parameters tested were the area of the 95% confidence ellipse enclosing the center of pressure (COP; [A95]) and COP path length.

RESULTS

Zolpidem significantly increased the A95 (both eyes conditions at all time points) and path length of COP. PR-M had no effect on A95 (both "eyes closed" and "eyes open" conditions at all time points) compared with placebo and increased COP path length by 10% at 4 h post-dose in open but not closed eyes condition. No serious adverse events were observed.

CONCLUSIONS

In older adults, evening PR-M intake did not impair postural stability during the night. The postural instability with zolpidem demonstrated assay sensitivity and validated the outcome.

Can a simple balance task be used to assess fitness for duty?

Human fatigue, caused by sleep loss, extended wakefulness, and/or circadian misalignment, is a major cause of workplace errors, incidents and accidents. In some industries, employees are required to undertake fitness for duty testing at the start of a shift to identify instances where their fatigue risk is elevated, so that minimisation and/or mitigation strategies can be implemented. Postural balance has been proposed as a fitness for duty test for fatigue, but it is largely untested. Therefore, the purpose of this study was to examine the impact of sleep loss, extended wakefulness and circadian phase on postural balance. Fourteen male participants spent 10 consecutive days in a sleep laboratory, including three adaptation days and eight simulated shiftwork days. To simulate a quickly rotating roster, shiftwork days were scheduled to begin 4h later each day, and consisted of a 23.3-h wake episode and a 4.7-h sleep opportunity. Every 2.5h during wake, balance was measured while standing as still as possible on a force platform with eyes open for one minute, and eyes closed for one minute. Subjective sleepiness was assessed using the Karolinska Sleepiness Scale. Core body temperature, continuously recorded with rectal thermistors, was used to determine circadian phase. For measures of postural balance and subjective sleepiness, data were analysed using three separate repeated measures ANOVA with two within-subjects factors: circadian phase (six phases) and prior wake (nine levels). For subjective sleepiness, there was a significant effect of prior wake and circadian phase. In particular, sleepiness increased as prior wake increased, and was higher during biological night-time than biological daytime. For the eyes open balance task, there was no effect of prior wake or circadian phase. For the eyes closed balance task, there was a significant effect of circadian phase such that balance was poorer during the biological night-time than biological daytime, but there was no effect of prior wake. These results indicate that postural balance may be a viable tool for assessing fatigue associated with time of day, but may not be useful for assessing fatigue associated with extended hours of wake.

Tolerability, pharmacokinetics and night-time effects on postural sway and critical flicker fusion of gaboxadol and zolpidem in elderly subjects

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT

Body sway increases in older adults and may lead to an increase in the risk of falling. The problem of impaired stability in the elderly may be compounded by the use of hypnotics, which have been associated with an increased risk of next-day falls as well as drowsiness. The potential adverse effects of hypnotic drugs on steadiness may be exacerbated during the night, in the event that an individual needs to get out of bed.

WHAT THIS STUDY ADDS

This study examines the effects of gaboxadol (an investigational treatment for insomnia), zolpidem (a current hypnotic included as an active control) and placebo on body sway and attention/information processing ability following bedtime dosing in elderly subjects who were woken during the night for assessments. Zolpidem and gaboxadol increased body sway at various time points during the night relative to placebo; at 1.5 h post dose, the time of peak concentrations of both drugs, gaboxadol produced less impairment than zolpidem. Compared with placebo, neither gaboxadol nor zolpidem impaired attention/information-processing ability as assessed by critical flicker fusion.

AIMS

To evaluate tolerability, pharmacokinetics and night-time effects on body sway and critical flicker fusion (CFF) of gaboxadol following bedtime dosing in healthy elderly subjects.

METHODS

Subjects (17 women, seven men) aged 65-75 years received gaboxadol 10 mg, zolpidem 5 mg (active control) or placebo at 22.00 h in a three-period, randomized, double-blind crossover study. They were awakened during the night for evaluation of body sway and CFF. Pharmacokinetics of gaboxadol were assessed during a fourth single-blind treatment period. Adverse events were recorded throughout the study.

RESULTS

The number of subjects with adverse events was 14 for gaboxadol 10 mg, seven for zolpidem and nine for placebo; most were mild or moderate in intensity. Two women discontinued the study following gaboxadol; one vomited and one experienced a severe vasovagal syncope after venepuncture. Mean gaboxadol t(max) was 2 h, t((1/2)) was 1.7 h, AUC(0-infinity) was 430 ng.h ml(-1) and C(max) was 139 ng ml(-1). At 1.5 h and 4 h post dose, zolpidem increased body sway relative to placebo (P < 0.01). Gaboxadol increased body sway at 4 h (P < 0.001) and 8 h (P < 0.05) relative to placebo. At 1.5 h, the time point closest to peak drug concentrations, zolpidem increased body sway compared with gaboxadol (P < 0.01). Gaboxadol and zolpidem had no effects on CFF vs. placebo.

CONCLUSIONS

A bedtime dose of gaboxadol 10 mg was generally well tolerated. Changes in body sway at 1.5 h after bedtime dosing were smaller with gaboxadol 10 mg than with zolpidem 5 mg, whereas changes were similar at 4 h for both treatments and returned to near baseline at 8 h.

Next-day residual effects of gaboxadol and flurazepam administered at bedtime: a randomized double-blind study in healthy elderly subjects

OBJECTIVE

To evaluate the next-day residual effects of the novel hypnotic, gaboxadol, following bedtime dosing in healthy elderly subjects.

METHODS

Healthy women (N = 15) and men (N = 10) aged 65-79 years received a single bedtime (22:00 h) dose of gaboxadol 10 mg, flurazepam 30 mg (positive control), and placebo in a randomized, double-blind, crossover study. Measures of information processing and psychomotor performance (choice reaction time, critical flicker fusion, digit symbol substitution, compensatory tracking, body sway), memory (immediate and delayed word recall), and daytime sleepiness (Multiple Sleep Latency Test), as well as subjective ratings (line analog rating scales, Leeds Sleep Evaluation Questionnaire), were obtained starting at 07:00 h the following morning. Adverse events were recorded.

RESULTS

Gaboxadol did not show next-day impairments versus placebo on any pharmacodynamic measures whereas the positive control, flurazepam, did show impairments versus placebo on most measures. Gaboxadol showed improvements versus placebo on some measures including subjective rating of next-day alertness/clumsiness on the Leeds Sleep Evaluation Questionnaire. Gaboxadol was generally well-tolerated; there were no serious adverse experiences and no subjects discontinued due to an adverse experience.

CONCLUSIONS

A single oral bedtime dose of gaboxadol 10 mg did not have next-day residual effects in healthy elderly subjects, as measured by a range of pharmacodynamic assessments, in contrast to the clear impairments produced by flurazepam 30 mg.